- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01858051
Vitamin D Status in Lower Extremity Joint Replacement Surgery Patients
Bolus vs. Divided Cholecalciferol Dosing to Optimize Perioperative Vitamin D Status for Joint Replacement Surgery
In the United States, ~1 million elective hip or knee replacement surgeries are performed annually. With estimated surgical site infection (SSI) rates as high as 2.5%, this represents ~25,000 patients at risk of potentially avoidable morbidity following lower extremity joint replacement surgery. Although SSIs only account for 20% of all HAIs, they are a major risk factor for prosthetic joint infections (PJIs). Furthermore, UTIs have also been identified as an independent risk factor for infections of implanted hardware.
In general, the majority of PJIs become apparent within 3 months of hardware implantation, but deep infections may not be evident for up to one year after surgery. Hardware infections result in delayed healing, repeated surgical interventions, and long-term antibiotic therapy. PJIs are associated with an average increase in hospital LOS by 14 days, additional expenditures of up to $50,000 per infected joint, and a doubling of the mortality rate compared to uninfected lower extremity joint replacements.
Recent work from our group suggests that vitamin D insufficiency may be a risk factor for perioperative HAIs. The prevalence of vitamin D insufficiency is approximately 40% in elective joint replacement surgery patients, and perioperative 25(OH)D levels drop 30-40% in the setting of surgical stress, remaining 20% below baseline up to 3 months after surgery. To date, perioperative vitamin D optimization strategies have not been reported. Therefore, our goal is to study the effect of a single (pre-operative) versus a divided (pre-operative and on post-operative day 1) dose of cholecalciferol on perioperative vitamin D status in patients scheduled for elective hip or knee joint replacement surgery.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02114
- Massachusetts General Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male or female
- Age ≥18 years
- English or Spanish speaking
- Scheduled for preoperative clinic assessment
- Scheduled to have elective hip or knee joint replacement surgery
- Not taking more than 1000 IU of either cholecalciferol or ergocalciferol daily
Exclusion Criteria:
- Unable to provide consent
- Inability to comply with study protocol
- History of anemia (hematocrit <25%)
- History of renal stones or hypercalcemia
- Conditions that can cause hypercalcemia (e.g. metastatic cancer, sarcoidosis, myeloma)
- Medications that affect vitamin D metabolism (e.g. anti-epileptics, tuberculosis medication)
- Already enrolled or planning to enroll in a research study that would conflict with full participation in the current study or confound the observation or interpretation of the study findings
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Cholecalciferol Bolus Dose
70 patients will receive a bolus pre-operative oral dose of 150,000 IU cholecalciferol 3-7 days before surgery
|
|
Active Comparator: Cholecalciferol Divided Dose
70 patients will receive an oral 100,000 IU cholecalciferol dose 3-7 days before surgery and an additional oral 50,000 IU cholecalciferol dose on post-operative day 1
|
|
Placebo Comparator: Sugar Pill
35 patients will receive a placebo pill orally 3-7 days before surgery
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in vitamin D status 5 days following supplementation with cholecalciferol
Time Frame: Patients will be followed between the initial preoperative evaluation day and an average duration of 5 days
|
Subjects will receive 150,000 IU or 100,000 IU cholecalciferol (vs.
placebo) 3-7 days before surgery during their pre-operative assessment.
Vitamin D status on the day of pre-operative assessment will be compared to vitamin D status on the day of surgery.
To assess vitamin D status, we will measure serum: 1) 25-hydroxyvitamin D; 2) Parathyroid hormone; 3) Vitamin D binding protein; 4) LL-37; 5) Albumin; and 6) Calcium levels.
|
Patients will be followed between the initial preoperative evaluation day and an average duration of 5 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in pre-surgical vitamin D status 1 day after surgery
Time Frame: Patients will be followed between the day of surgery and an average duration of 1 day after surgery
|
Subjects will receive either pre-operative supplementation with 150,000 IU or pre-operative supplementation with 100,000 IU cholecalciferol plus 50,000 IU cholecalciferol on post-operative day 1 (vs.
placebo).
Vitamin D status will be compared between the day of surgery and post-operative day 1.
To assess vitamin D status, we will measure: 1) 25-hydroxyvitamin D; 2) Parathyroid hormone; 3) Vitamin D binding protein; 4) LL37; 5) Albumin; and 6) Calcium levels.
|
Patients will be followed between the day of surgery and an average duration of 1 day after surgery
|
Change in pre-surgical vitamin D status 2 weeks after surgery
Time Frame: Patients will be followed between the day of surgery and an average duration of 14 days after surgery
|
Subjects will receive either pre-operative supplementation with 150,000 IU or pre-operative supplementation with 100,000 IU cholecalciferol plus 50,000 IU cholecalciferol on post-operative day 1 (vs.
placebo).
Vitamin D status will be compared between the day of surgery and post-operative day 10-18.
To assess vitamin D status, we will measure: 1) 25-hydroxyvitamin D; 2) Parathyroid hormone; 3) Vitamin D binding protein; 4) LL37; 5) Albumin; and 6) Calcium levels.
|
Patients will be followed between the day of surgery and an average duration of 14 days after surgery
|
Change in pre-surgical vitamin D status 3 months after surgery
Time Frame: Patients will be followed between the day of surgery and an average of 90 days after surgery
|
Subjects will receive either pre-operative supplementation with 150,000 IU or pre-operative supplementation with 100,000 IU cholecalciferol plus 50,000 IU cholecalciferol on post-operative day 1 (vs.
placebo).
Vitamin D status will be compared between the day of surgery and post-operative day 80-100.
To assess vitamin D status, we will measure: 1) 25-hydroxyvitamin D; 2) Parathyroid hormone; 3) Vitamin D binding protein; 4) LL37; 5) Albumin; and 6) Calcium levels.
|
Patients will be followed between the day of surgery and an average of 90 days after surgery
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of post-operative complications within 3 months of surgery
Time Frame: Patients will be followed between the day of surgery and an average of 90 days after surgery
|
Subjects will receive either pre-operative supplementation with 150,000 IU or pre-operative supplementation with 100,000 IU cholecalciferol plus 50,000 IU cholecalciferol on post-operative day 1 (vs.
placebo).
The incidence of post-operative complications will be assessed between the day of surgery and post-operative day 80-100.
To assess the incidence of post-surgical complications, we will measure rates of: 1) pneumonia; 2) urinary tract infection; 3) surgical site infection; 5) sepsis/bacteremia; 6) infected hardware; 7) hospital readmission; and 8) mortality.
|
Patients will be followed between the day of surgery and an average of 90 days after surgery
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Sadeq A Quraishi, MD, MMSc, Harvard Medical School, Massachusetts General Hospital
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Metabolic Diseases
- Nutrition Disorders
- Musculoskeletal Diseases
- Deficiency Diseases
- Malnutrition
- Bone Diseases
- Bone Diseases, Metabolic
- Calcium Metabolism Disorders
- Vitamin D Deficiency
- Rickets
- Avitaminosis
- Physiological Effects of Drugs
- Micronutrients
- Vitamins
- Bone Density Conservation Agents
- Calcium-Regulating Hormones and Agents
- Vitamin D
- Cholecalciferol
Other Study ID Numbers
- 2013P001071
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hypovitaminosis D
-
Hospices Civils de LyonCompleted
-
Azienda Ospedaliero-Universitaria Consorziale Policlinico...Silvana De Giorgi; Davide Bizzoca; Angela NotarnicolaRecruitingHypovitaminosis DItaly
-
Madigan Army Medical CenterCompletedHypovitaminosis DUnited States
-
University of TromsoCompleted
-
Jewish General HospitalMcGill UniversityCompleted
-
Boston UniversityCompletedVitamin D Deficiency | Vitamin E Deficiency | Hypovitaminosis AUnited States
-
Bangabandhu Sheikh Mujib Medical University, Dhaka...Completed
-
Massachusetts General HospitalBio-Tech Pharmacal, Inc.CompletedHypovitaminosis DUnited States
-
Harokopio UniversityUniversity College Cork; FrieslandCampinaCompletedHypovitaminosis D | Deficiency of MicronutrientsGreece
-
Chulalongkorn UniversityUnknownVitamin D2 Supplementation in Vitamin D InsufficiencyThailand
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States